Questcor's Acthar shows positive results for systemic lupus erythematosus Questcor announced that results from the first modern clinical study examining the use of H.P. Acthar Gel in systemic lupus erythematosus has been published in the journal LUPUS. The results reveal that Acthar treatment resulted in significant improvements in certain clinical outcome measures that indicate a reduction of lupus disease activity. The drug was generally well-tolerated during the course of the study.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.
Mallinckrodt price target lowered to $77 from $90 at Leerink Leerink lowered its price target for Mallinckrodt (MNK) shares to $77 citing a heightened risk profile from the Questcor (QCOR) acquisition and significant earnings concentration in Acthar. The firm says it remains on the sidelines with a Market Perform rating on Mallinckrodt.
Mallinckrodt remains favorite specialty pharmaceutical name, says UBS UBS said Mallinckrodt (MNK) remains its favorite specialty pharmaceutical name following the company's update on its merger with Questcor (QCOR). The firm sees estimates increasing following the close of the transaction, the divestiture of the Medical Imaging division, and the reinvestment in higher margin assets. UBS has a Buy rating with a $94 price target on Mallinckrodt.